Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli

被引：45

作者：

Denamur, E

Tenaillon, O

Deschamps, C

Skurnik, D

Ronco, E

Gaillard, JL

Picard, B

Branger, C

Matic, I

机构：

[1] INSERM, Fac Med Necker, U571, F-75730 Paris, France

[2] INSERM, U722, Paris, France

[3] Univ Paris 07, Paris, France

[4] GHU Nord, AP HP, Microbiol Lab, Colombes, France

[5] GHU Nord, AP HP, Microbiol Lab, Paris, France

[6] GHU Nord, AP HP, Microbiol Lab, Bobigny, France

[7] GHU Ouest, Microbiol Lab, AP HP, Garches, France

[8] Univ Paris 05, Paris, France

来源：

GENETICS | 2005年 / 171卷 / 02期

关键词：

D O I：

10.1534/genetics.105.045526

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

In studying the interplay between mutation frequencies and antibiotic resistance among Escherichia coli natural isolates, we observed that modest modifications of mutation frequency may significantly influence the evolution of antibiotic resistance. The strains having intermediate mutation frequencies have significantly more antibiotic resistances than strains having low and high ruination frequencies.

引用

收藏

页码：825 / 827

页数：3

相关论文

共 22 条

[1] Mismatch repair and response to DNA-damaging antitumour therapies [J].

Bignami, M ;

Casorelli, I ;

Karran, P .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (15) :2142-2149

[2]

Blázquez J, 2003, CLIN INFECT DIS, V37, P1201, DOI 10.1086/378810

[3] IMMUNE SURVEILLANCE IN COLORECTAL-CARCINOMA [J].

BRANCH, P ;

BICKNELL, DC ;

ROWAN, A ;

BODMER, WF ;

KARRAN, P .

NATURE GENETICS, 1995, 9 (03) :231-232

[4] Genetic background of Escherichia coli and extended-spectrum β-lactamase type [J].

Branger, C ;

Zamfir, O ;

Geoffroy, S ;

Laurans, G ;

Arlet, G ;

Thien, HV ;

Gouriou, S ;

Picard, B ;

Denamur, E .

EMERGING INFECTIOUS DISEASES, 2005, 11 (01) :54-61

[5] The population genetics of ecological specialization in evolving Escherichia coli populations [J].

Cooper, VS ;

Lenski, RE .

NATURE, 2000, 407 (6805) :736-739

[6] High frequency of mutator strains among human uropathogenic Escherichia coli isolates [J].

Denamur, E ;

Bonacorsi, S ;

Giraud, A ;

Duriez, P ;

Hilali, F ;

Amorin, C ;

Bingen, E ;

Andremont, A ;

Picard, B ;

Taddei, F ;

Matic, I .

JOURNAL OF BACTERIOLOGY, 2002, 184 (02) :605-609

[7]

Funchain P, 2000, GENETICS, V154, P959

[8] Mutator bacteria as a risk factor in treatment of infectious diseases [J].

Giraud, A ;

Matic, I ;

Radman, M ;

Fons, M ;

Taddei, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :863-865

[9] Costs and benefits of high mutation rates: Adaptive evolution of bacteria in the mouse gut [J].

Giraud, A ;

Matic, I ;

Tenaillon, O ;

Clara, A ;

Radman, M ;

Fons, M ;

Taddei, F .

SCIENCE, 2001, 291 (5513) :2606-2608

[10] High mutation frequencies among Escherichia coli and Salmonella pathogens [J].

LeClerc, JE ;

Li, BG ;

Payne, WL ;

Cebula, TA .

SCIENCE, 1996, 274 (5290) :1208-1211